Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.
- DOI
- 10.1038/s41523-026-00950-z
- Published
- 2026 Apr 27
- Container
- NPJ breast cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41523-026-00950-z,
title = {Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.},
author = {O'Shaughnessy J and Bidard FC and Neven P and Casalnuovo ML and Aftimos P and Saura C and Harbeck N and Carey LA and Curigliano G and Garcia-Saenz JA and Abad MF and Paula L and Park YH and Ozyilkan O and Munoz M and Barrett E and Cao S and Chawla A and Jhaveri KL},
year = {2026},
journal = {NPJ breast cancer},
doi = {10.1038/s41523-026-00950-z},
url = {https://doi.org/10.1038/s41523-026-00950-z}
}RIS
TY - JOUR TI - Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial. AU - O'Shaughnessy J AU - Bidard FC AU - Neven P AU - Casalnuovo ML AU - Aftimos P AU - Saura C AU - Harbeck N AU - Carey LA AU - Curigliano G AU - Garcia-Saenz JA AU - Abad MF AU - Paula L AU - Park YH AU - Ozyilkan O AU - Munoz M AU - Barrett E AU - Cao S AU - Chawla A AU - Jhaveri KL PY - 2026 JO - NPJ breast cancer DO - 10.1038/s41523-026-00950-z UR - https://doi.org/10.1038/s41523-026-00950-z ER -
APA
J, O., FC, B., P, N., ML, C., P, A., C, S., N, H., LA, C., G, C., JA, G., MF, A., L, P., YH, P., O, O., M, M., E, B., S, C., A, C., & KL, J. (2026). Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.. NPJ breast cancer. https://doi.org/10.1038/s41523-026-00950-z
Source records
- pubmed · retrieved 2026-09-26T04:28:43.776Z